Natural Killer Cell

Generic Name: Natural Killer Cell

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: IZR558KO53

Background: Natural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all lymphocytes in human peripheral blood. Once completely differentiated, NK cells lack B (CD19-) and T(CD3-) lymphocyte markers...

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Venetoclax
Drug: NK Cells

First Posted Date: 2023-04-28

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT05834244

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Quadruple Immunotherapy for Neuroblastoma

Phase 2

Recruiting

Conditions: Neuroblastoma Recurrent

Interventions: Biological: Natural killer cell
Drug: Dinutuximab beta
Drug: Interleukin-2
Drug: Granulocyte-Macrophage Colony-Stimulating Factor
Drug: Spironolactone
Drug: Naxitamab

First Posted Date: 2023-03-06

Last Posted Date: 2024-10-03

Lead Sponsor: Hong Kong Children's Hospital

Target Recruit Count: 29

Registration Number: NCT05754684

Locations: 🇭🇰
Hong Kong Children's Hospital, Hong Kong, Hong Kong

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Phase 1

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: Dinutuximab
Biological: NK Cells
Drug: Lenalidomide

First Posted Date: 2015-10-12

Last Posted Date: 2024-11-05

Lead Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Target Recruit Count: 13

Registration Number: NCT02573896

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
C.S Mott Children's Hospital, Ann Arbor, Michigan, United States

and more 8 locations

Natural Killer Cells and Bortezomib to Treat Cancer

Phase 1

Completed

Conditions: Colon/Rectal Ca
Chronic Myeloid Leukemia (CML)
Pancreatic Ca
Multiple Myeloma
Carcinoma, Non-Small -Cell Lung

Interventions: Biological: NK cells
Drug: Bortezomib

First Posted Date: 2008-07-23

Last Posted Date: 2024-12-19

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 35

Registration Number: NCT00720785

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy